The human gut consists of several thousand species of prokaryotes including bacteria and archaea that have multiple metabolic and constitutive effects. A large proportion of these species are autochthonous, i.e., bacteria that are present among the gut mucosal niches that have evolved to survive in this ecological space while presumably providing a beneficial effect to the host [1] . Changes in this flora have been associated with inflammatory bowel disease, cirrhosis, and irritable bowel syndrome (IBS) [2] [3] [4] . In most disease states, there is a relative increase in potentially pathogenic bacteria compared to healthy hosts along with a reduction in the overall bio-diversity. A stumbling block in the characterization of the gut microbiome is the inability of the majority of species, especially anaerobic species, to be grown using standard culture methods [5] . For example, it has been suggested that less than 1 % of an environmental community can be cultured using typical growth media [6] . Initially, cloning and sequencing was performed to elucidate the community in the human gut but this was both tedious and expensive [7] . The introduction of NextGen sequencing technology has revolutionized the field of microbial ecology and allows for the rapid in-depth analysis of many different environmental samples. To put this into perspective, the typical fluorescent sequencer will produce 96 reads per day while the NextGen Roche GS-FLX will produce 500,000 reads per day. Thus, the new technology produces 20 years worth of cloning and sequencing in an afternoon. Furthermore, multitag pyrosequencing (MTPS) has become a powerful and routine method for microbial community analysis [8] [9] [10] [11] that takes advantage of this high-throughput technology. This methodology essentially barcodes samples that are then mixed and sequenced on one highthroughput sequencing run and then the reads are sorted into their corresponding samples based on the barcode. Specific amplification primers can be used to selectively amplify variable regions of the 16S rRNA of archaea or bacteria to enumerate these components in the gut microbiome. Therefore, the profusion of recent studies that evaluate the culture-independent methods of fecal bacterial enumeration opens an interesting chapter in our understanding of this complex system. It has been known for decades that adult humans excrete methane and approximately one-third of all Americans produce detectable methane [12, 13] . Methane is produced in the human colon by methanogenic archaea by reducing CO 2 and using H 2 as the electron donor (4H 2 ? CO 2 ? CH 4 ? 2H 2 O). Methanobrevibacterium smithii is the most common methanogen in the human colon, with levels ranging from undetectable to 10 10 /g dry weight [14] . Methanogens compete for available hydrogen gas with dissimilatory sulfate reducing bacteria [15] . Methane was initially thought to be an inert gas, however there is experimental and clinical evidence that methane is capable of reducing intestinal transit [16] . While the exact growth rate of M. smithii is unclear, the in vivo energetics of the methane formation reaction realistically makes this a slowgrowing organism. The reduction in intestinal transit induced by methane production could potentially be a survival mechanism to allow numbers of this organism to grow in the intestine, but this is unproven. The study by Kim et al. in this issue highlights the role of quantitative PCR for the detection of M. smithii in a case-control study of patients with constipation-predominant IBS (C-IBS) [17] . They compared the presence of this species in methane-producing constipation-predominant IBS patients and compared them to non-methane-producing IBS patients and found that while this organism was detected in both groups, its abundance was clearly higher in those with C-IBS. Interestingly, they also demonstrated a correlation between the concentration of the M. smithii and its functional aspect, i.e., production of methane in the exhaled air. This study is provocative, although limited by its sample size, in that it shows a linkage between function and presence of M. smithii using culture-independent techniques. As prior studies have shown a significant difference between the stool and intestinal mucosal microbiome, it would have been interesting to compare the abundance of the organism on the colonic mucosa and correlate that with function [18, 19] . Also, as a significant proportion of methane is expelled as flatus, a methane breath test may underestimate methane production. The use of the primer just for M. smithii limits the detection of archaea species and also underestimates the role other species might be playing in overall methane production. However, this paper opens up an exciting chapter in IBS investigation which, if confirmed in larger populations, a concentration of M. smithii can be used as a biomarker for diagnosis as well as response to therapy.
